Insights

For health systems, clinical AI maturity is not measured by how sophisticated the technology is. It is measured by whether the technology helps clinicians recognize what matters, act sooner, and carry less cognitive burden.

By Marc Zemel, Chief Executive Officer, Retia Medical

The patients in an acute care hospital today are sicker than the patients in that same hospital a decade ago. Anyone who is not acutely ill is now treated in an ambulatory setting or monitored at home. Med-surg beds increasingly hold patients who once would have been in an ICU, and ICU beds hold patients who are more complex than ever. Staffing has not moved in proportion.

That is the environment into which health systems are deploying artificial intelligence, advanced analytics, and clinical decision support. It should change how leaders evaluate those tools. The question is no longer how intelligent the technology is. It’s whether the technology makes it easier for a clinician to recognize what matters and act at the right moment.

A platform that adds another screen, another alert, or another workflow to manage has answered the wrong question. Sophistication without usability creates friction, and friction determines whether an innovation becomes part of care delivery or sits unused at the edge of it.

The ICU does not have a data shortage

Critical care units generate an enormous volume of physiologic data. More data does not produce more clarity. Clinicians must continuously determine which signals matter, which changes require intervention, and which alerts safely wait, all while caring for multiple complex patients.

The distinction worth holding onto is between raw data, information presented with context, and actionable intelligence delivered at a moment when a clinician is able to do something with it. Bruce Brandes, a 35-year veteran of healthcare technology who serves on our Strategic Advisory Board, frames the timing problem plainly: “Do not tell me about something I do not need to know until tomorrow. Do not tell me something I needed to know yesterday.”

A measurement without context adds to the workload. An alert that repeatedly proves irrelevant trains the user to discount it. An insight arriving too late is accurate and clinically useless.

Brandes compares monitoring on a med-surg floor to the warning lights on a car dashboard. There are a limited number of them and each means something specific: amber to watch, red to stop. The ICU is closer to a cockpit. A pilot monitors many dimensions at once and cannot give all of them equal attention, so the instruments have to surface what is most critical and what signals a developing problem. Missing an indicator at altitude is not comparable to a low tire pressure warning.

That is the shift clinical AI has to enable, from collecting more to clarifying what matters.

Workflow belongs in the governance conversation

As health systems build governance for clinical AI, they are focused on validation, transparency, bias, privacy, security, and accountability. Governance also has to account for what a tool does to the people delivering care.

Leaders should ask whether a technology introduces additional steps, increases false-positive alerts, interrupts established workflows, or creates ambiguity about who owns the final decision. They should ask whether clinicians understand the basis of an insight, and whether the technology has been validated for its intended clinical use.

These are not adoption questions. They are questions of safety, trust, and organizational readiness. Clinical teams use technology when it supports how care is delivered, provides credible information, and preserves professional judgment. The physician and bedside team remain the decision-makers. Technology helps them see sooner and decide with greater confidence. It should not distance them from the patient or obscure the reasoning behind a recommendation.

The best technology is the least visible

Healthcare has already paid for this lesson. As Brandes puts it, “We are the only industry that spent billions of dollars on technology that made people’s lives harder, not easier.”

The next generation of clinical tools has to reverse that relationship. The technology adapts to the workflow rather than the reverse. The best of it is nearly invisible. It does not compete for attention or force clinicians to hunt for relevance. It fits the rhythm of care, surfaces what matters, and gets out of the way.

The harder problem is rarely the technology itself. Brandes argues that the status quo in healthcare has usually prevailed not because a technology failed, but because the operational work of putting it into practice was underestimated. Change management is where transformation succeeds or stalls.

That standard matters more under workforce pressure. Technology does not solve staffing shortages. It either intensifies the burden on limited teams or reduces it. A tool that helps clinicians prioritize patients and interpret complex trends extends the reach of clinical expertise. A tool that creates noise consumes capacity no one has to spare. Usability is a strategic outcome, not a feature to evaluate after procurement.

The part executives rarely say out loud

It has never been harder to run a hospital. Acuity is rising, the cost of delivering care is rising faster, and reimbursement is fixed by long-term agreements with Medicare, Medicaid, and commercial payers. Margins that were already thin are under a kind of pressure they have not seen before.

That creates a tension health system leaders live with constantly and discuss rarely. Brandes names it directly: “Sometimes doing the right thing is not good for our business and our bottom line.”

The implication for anyone bringing technology into a health system is that clinical merit alone is not sufficient. A tool has to be justifiable both clinically and economically. Vendors who ignore the second half are asking executives to absorb a cost with no mechanism to recover it. Aligning those incentives is a larger industry problem. Being honest about it is the starting point.

A higher bar for clinical AI

Health system leaders do not need another promise that AI will transform care. They need a practical standard for deciding which technologies are ready to create value in demanding clinical environments.

Before scaling a clinical AI or decision-support tool, leaders should ask:

• • Is the insight clinically validated, transparent, and explainable?
  • Does it arrive at a moment when the care team is able to act on it?
  • Does it reduce cognitive burden rather than add another source of noise?
  • Does it fit the clinical workflow and preserve clinician judgment?
  • Is the problem it solves among the most critical the organization faces this year? Any organization absorbs a finite amount of change at one time.
  • Is the organization able to measure its effect on outcomes, capacity, workforce, and economics?

These questions move the conversation past technical capability and toward clinical maturity.

The future of clinical AI will not be defined by how much data a health system collects or how many algorithms it deploys. It will be defined by whether technology turns complexity into clarity, helping clinicians recognize what matters, act sooner, and give more of their attention to the patient in front of them.

For health systems, that is the intelligence that matters.

About Retia Medical

Retia Medical is a cardiovascular intelligence software company. Its FDA 510(k)-cleared, monitor-agnostic Argos Infinity™ platform runs on existing bedside and tele-ICU infrastructure to deliver cardiovascular insight at scale. The company is headquartered in White Plains, NY. Visit www.retiamedical.com and follow us on LinkedIn.